IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
0.7300
+0.0400 (5.80%)
At close: Mar 16, 2026, 4:00 PM EDT
0.7012
-0.0288 (-3.95%)
Pre-market: Mar 17, 2026, 9:12 AM EDT
IceCure Medical Revenue
In the year 2025, IceCure Medical had annual revenue of $3.38M with 2.67% growth. IceCure Medical had revenue of $1.28M in the quarter ending December 31, 2025, with 46.17% growth.
Revenue (ttm)
$3.38M
Revenue Growth
+2.67%
P/S Ratio
17.94
Revenue / Employee
$45,076
Employees
66
Market Cap
53.38M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.38M | 88.00K | 2.67% |
| Dec 31, 2024 | 3.29M | 62.00K | 1.92% |
| Dec 31, 2023 | 3.23M | 144.00K | 4.67% |
| Dec 31, 2022 | 3.09M | -1.05M | -25.45% |
| Dec 31, 2021 | 4.14M | 270.00K | 6.98% |
| Dec 31, 2020 | 3.87M | 2.24M | 137.74% |
| Dec 31, 2019 | 1.63M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Accuray | 436.97M |
| Outset Medical | 119.48M |
| TELA Bio | 77.06M |
| Myomo | 40.93M |
| Cytosorbents | 36.98M |
| electroCore | 29.84M |
| Sensus Healthcare | 27.48M |
| Spectral AI | 23.17M |
ICCM News
- 59 minutes ago - IceCure Reports 2025 Full Year Financial & Operational Results - PRNewsWire
- 6 days ago - U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer - PRNewsWire
- 7 days ago - IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026 - PRNewsWire
- 8 days ago - American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer - PRNewsWire
- 14 days ago - IceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense® Cryoablation Safe and Effective in Treatment of Breast Fibroadenomas - PRNewsWire
- 21 days ago - IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026 - PRNewsWire
- 25 days ago - IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense®, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation - PRNewsWire
- 4 weeks ago - IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense® - PRNewsWire